Aug 29, 2019
BioGenerator-supported startup noted for its ‘promising technology’ to more quickly and affordably bring vaccines to market
ST. LOUIS – St. Louis bioscience startup VaxNewMo is developing broader and more affordable vaccines faster with its patented technology. The company’s breakthrough research to combat “superbugs” is currently featured in the national, peer-reviewed publication Proceedings of the National Academy of Sciences (PNAS).
In the article, “A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae,” the case is made for VaxNewMo’s promising technology for the rapid development of effective vaccines against emerging bacterial threats. Klebsiella can cause severe – often fatal – disease in healthy people, and with several strains showing resistance to multiple drugs, creating a vaccine against it is the most effective way to combat it.
VaxNewMo’s new vaccine targets 70 percent of all hypervirulent Klebsiella pneumonia strains and could eventually help stem the global spread of this particularly dangerous pathogen. Having the company’s work published in PNAS highlights the significant need for a vaccine against hypervirulent K. pneumoniae. Next up for VaxNewMo and its new vaccine is further commercial development in order to advance its product to the clinic.
“We are thrilled and privileged to have this project accepted for publication in PNAS,” said Christian Harding, Ph.D., VaxNewMo CEO. “We worked with an international team of scientists with cross-complementary skills to design and build a vaccine that is protective and ready for commercial development.”
VaxNewMo is a BioGenerator Labs client. BioGenerator, the investment arm of BioSTL, has provided VaxNewMo with non-dilutive grant funding and business coaching for complex license negotiations, team building, and business strategy. Through its Grants-2-Business program, which coaches entrepreneurs through the process of submitting strong grant applications, BioGenerator has helped VaxNewMo win two federal grants totaling more than $500,000, as well as a $50,000 Arch Grant.
“This is the second time in the last six months that VaxNewMo’s breakthrough approach to developing glycoconjugate vaccines has been recognized in major, national publications for the team’s promise of accelerating new and much more effective vaccines to market,” said Harry Arader, Director of Entrepreneur Development at BioGenerator and VaxNewMo Business Coach. “BioGenerator is proud to support Dr. Harding and VaxNewMo’s talented team to help them demonstrate that their technology will work and make a big difference protecting the most vulnerable among us.”
VaxNewMo is an early-stage biotechnological company that develops next-generation conjugate vaccines against infectious diseases using its proprietary in vivo conjugating technology. VaxNewMo employs its proprietary conjugating enzyme technology to covalently attach a target bacterial polysaccharide to an acceptor protein all within the lab-safe E. coli bacterium. This approach bypasses the dependency on synthetic chemistry to manufacture conjugate vaccines, streamlining their production. Currently VaxNewMo is developing a pneumococcal conjugate vaccine and a Klebsiella pneumoniae conjugate vaccine. VaxNewMo is headquartered in St. Louis.
BioGenerator, the investment arm of BioSTL, produces a sustained pipeline of successful bioscience companies and entrepreneurs in St. Louis by creating, growing and investing in promising new enterprises. Visit www.BioGenerator.org for additional information, and follow us on LinkedIn linkedin.com/company/BioGenerator and Twitter @BioGeneratorSTL.
CONTACT Maggie Crane | 314.422.6783 | email@example.com